Shares of the Illinois-based drugmaker Eli Lilly (NYSE: LLY) were up by 6% on heavy volume as of 1:45 p.m. ET Wednesday.

What sparked this latest rally? Ahead of the opening bell, Lilly announced that its early-stage Alzheimer's disease treatment, donanemab, slowed cognitive decline by a clinically meaningful 35% in a late-stage trial.

By contrast,  and Eisai's Food and Drug Administration (FDA)-approved Leqembi, slowed cognitive decline by 27% in a similar patient group, compared to placebo. That being said, there are key differences in the trials between these two drugs, making head-to-head comparisons impossible at this early juncture. 

Continue reading

Source Fool.com